Clinical Trials

A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Cancer Type

Chronic Lymphoid Leukemia, Lymphoma

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Daruka Mahadevan, MD, PhD

For more information about this study
View Details

About This Study

M22-716 is a Phase 1, FIH, open-label, dose escalation, dose expansion, biomarker/pharmacodynamic (PD) study of ABBV-319 in participants with relapsed or refractory (R/R) B-cell malignancies.